Key Takeaways ・The weight-loss drug tirzepatide reduced both body fat and tumor growth in obese mice with breast cancer.

Key takeaways: Less than 10% of adults receiving tirzepatide in clinical trials reported a serious adverse event. Gastrointestinal adverse events were common and increased with tirzepatide dosage.

Tirzepatide was superior to semaglutide in achieving standard and intensive cardiometabolic targets among patients with type ...

Studies were included if they were clinical- or randomized controlled trials investigating the performance of Tirzepatide against insulin in any of the following outcomes – Body weight, fasting ...

Tirzepatide reduces breast tumor growth in obese mice while improving metabolic health, offering hope as a dual-action cancer ...

Benefits were most prominent among women, patients older than 60 and those with a body mass index of 30 to 40.

In patients with obesity, tirzepatide improved cardiometabolic parameters and risk for cardiovascular disease, but the ...

A phase 3 clinical trial of tirzepatide, sold as Mounjaro, has demonstrated that if taken after an initial weight loss brought about by diet and lifestyle changes, the drug can lead to significant ...

In real-world cohort, percentage weight reduction at 1 year was 3.6%, 6.8%, and 11.9% with early and late discontinuation and nondiscontinuation, respectively.

Preliminary data from a large Phase 3 clinical trial is offering promising signs for a new anti-obesity drug. Called tirzepatide, the drug helped overweight and obese participants lose up to 22.5 ...

The 52-week SURPASS-4 trial (ClinicalTrials.gov: NCT03730662) is part of a phase 3 global clinical development program for tirzepatide, a novel, once-weekly, dual glucose-dependent insulinotropic ...